Johnson & Johnson has announced the latest advancements in Pulsed Field Ablation technology, highlighting multiple clinical and real-world studies to be presented at the Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JPHRS) meetings. Key presentations include new data on safety, efficacy, and workflow improvements intended to optimize irrigation and support consistent procedural outcomes in atrial fibrillation care. Specific sessions will address topics such as bilateral first pass isolation, the benefits of carina ablation in addition to pulmonary vein isolation, and sex differences in left atrial scar burden and ablation outcomes. Additionally, results from the QUEST AF study on the acute success of persistent atrial fibrillation ablation using a temperature-controlled, very high-power short-duration radiofrequency catheter will be presented. Johnson & Johnson MedTech continues to collaborate with the clinical community to expand real-world evidence around its VARIPULSE™ Platform and advance innovation in atrial fibrillation treatment.